A review of current developments in RNA modifications in lung cancer.

IF 5.3 2区医学 Q1 ONCOLOGY

Cancer Cell International Pub Date : 2024-10-25 DOI:10.1186/s12935-024-03528-6

Shujun Zhang, Yafeng Liu, Kaijie Liu, Xinjun Hu, Xinyu Gu

引用次数: 0

Abstract

Lung cancer has the highest incidence and mortality rates worldwide and is the primary cause of cancer-related death. Despite the rapid development of diagnostic methods and targeted drugs in recent years, many lung cancer patients do not benefit from effective therapies. The emergence of drug resistance has led to a reduction in the therapeutic effectiveness of targeted drugs, highlighting a crucial need to explore novel therapeutic targets. Many studies have found that epigenetic plays an important role in the occurrence of lung cancer. This review describes the biological function of epigenetic RNA modifications, such as m6A, m5C, m7G, and m1A, and recent advancements in their role in the development, progression, and prognosis of lung cancer. This review aims to provide new guidance for the treatment of lung cancer.

查看原文本刊更多论文

回顾肺癌 RNA 修饰的最新进展。

肺癌是全世界发病率和死亡率最高的癌症，也是癌症相关死亡的主要原因。尽管近年来诊断方法和靶向药物发展迅速，但许多肺癌患者并没有从有效的疗法中获益。耐药性的出现导致靶向药物的治疗效果下降，突出了探索新型治疗靶点的迫切需要。许多研究发现，表观遗传在肺癌的发生中起着重要作用。本综述介绍了表观遗传 RNA 修饰（如 m6A、m5C、m7G 和 m1A）的生物学功能，以及它们在肺癌的发生、发展和预后中作用的最新进展。本综述旨在为肺癌的治疗提供新的指导。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Cell International ONCOLOGY-

CiteScore

10.90

自引率

1.70%

发文量

360

审稿时长

1 months

期刊介绍： Cancer Cell International publishes articles on all aspects of cancer cell biology, originating largely from, but not limited to, work using cell culture techniques. The journal focuses on novel cancer studies reporting data from biological experiments performed on cells grown in vitro, in two- or three-dimensional systems, and/or in vivo (animal experiments). These types of experiments have provided crucial data in many fields, from cell proliferation and transformation, to epithelial-mesenchymal interaction, to apoptosis, and host immune response to tumors. Cancer Cell International also considers articles that focus on novel technologies or novel pathways in molecular analysis and on epidemiological studies that may affect patient care, as well as articles reporting translational cancer research studies where in vitro discoveries are bridged to the clinic. As such, the journal is interested in laboratory and animal studies reporting on novel biomarkers of tumor progression and response to therapy and on their applicability to human cancers.